Hansen Medical's Cary Vance Interviewed by The Life Sciences Report


SAN FRANCISCO, CA--(Marketwired - November 18, 2015) - Interventional radiology has been described as the surgery of the new millennium by Stanford Healthcare, offering less invasive procedures, more precise placement of catheters and, often, fewer complications for patients and higher throughput for healthcare facilities. Robotics is making this new area of medicine possible. Cary G. Vance, CEO of Hansen Medical Inc. (NASDAQ: HNSN), tells The Life Sciences Report about disruptive advances in interventional radiology.

The Life Sciences Report: How are robotic procedures helping new surgical approaches to emerge or providing alternatives to open surgeries?

Cary Vance: In key areas, intravascular robotics are leading the way to less invasive treatments of certain disease states. For example, robotic prostatic artery embolization is a possible treatment for benign prostatic hyperplasia or enlarged prostate. Robotics help the interventional radiologist perform this challenging procedure, which deals with tortuous anatomy where catheter stability is paramount. Patients are eager to learn more about this approach. They're very excited about the smaller incisions, possible quicker recovery times and the potential for fewer complications, compared to...

Continue reading this interview: Robotics Are Key to New Millennium Surgeries: Hansen Medical's Cary Vance

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

Hansen Medical Inc. is a sponsor of Streetwise Reports. Mr. Vance had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Vance and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Contact Information:

Jim Patrick